A Risk Model Based on Sorafenib-Response Target Genes Predicts the Prognosis of Patients with HCC

Sorafenib is used to treat digestive system tumors in patients who do not respond to or cannot tolerate surgery. However, the roles and inhibitory mechanisms of sorafenib against hepatocellular carcinoma (HCC) are unclear. Differentially expressed genes in tissues from responders and nonresponders t...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiang, Zeng, Jian, Li, Huanyu, Li, Feng, Jiang, Bin, Zhao, Ming, Liu, Zhuo, Li, Ruineng, Ma, Tiexiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256406/
https://www.ncbi.nlm.nih.gov/pubmed/35799605
http://dx.doi.org/10.1155/2022/7257738

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256406/
https://www.ncbi.nlm.nih.gov/pubmed/35799605
http://dx.doi.org/10.1155/2022/7257738

Ejemplares similares